Sandoz Unveils Biosimilar Pyzchiva®: A New Hope for 12 Million US Patients

Sandoz, a global leader in generic and biosimilar medicines, has launched Pyzchiva® (ustekinumab-ttwe), a biosimilar to Stelara®, in the US. This development brings new hope to around 12 million patients suffering from chronic inflammatory diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Pyzchiva® is expected to offer improved patient access and reduced healthcare system costs through its competitive pricing strategy.

Pyzchiva® is a human interleukin (IL)-12 and IL-23 antagonist, indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis. It is also approved for pediatric patients with moderate to severe plaque psoriasis and active psoriatic arthritis. The launch of Pyzchiva® builds on Sandoz's strategic ambition to become the number one biosimilar company in the US.



The US market for biosimilars is projected to grow at a CAGR of 17.6% from 2022 to 2032, reaching an estimated value of USD 1,26,019.67 million by 2032. This growth is driven by factors such as the rising prevalence of chronic diseases, cost-effectiveness, patent expirations, regulatory support, and increasing awareness and acceptance of biosimilars. The launch of Pyzchiva® is well-positioned to capitalize on this growth potential.

Pyzchiva® is expected to be priced around 15% to 35% lower than its reference medicine, Stelara®, making it a more affordable treatment option for patients and healthcare systems. This pricing strategy is expected to improve patient access to ustekinumab treatment, reduce healthcare system costs, and increase competition in the market. The potential for interchangeability in the first half of 2025 further enhances the appeal of Pyzchiva®, as it allows for automatic substitution at the pharmacy level.

In conclusion, the launch of Pyzchiva® by Sandoz in the US offers new treatment options for around 12 million patients suffering from chronic inflammatory diseases. With its competitive pricing strategy and potential for interchangeability, Pyzchiva® is well-positioned to improve patient access, reduce healthcare system costs, and contribute to the growth of the biosimilars market in the US. As the market for biosimilars continues to expand, the demand for innovative and cost-effective treatment options like Pyzchiva® is expected to drive further growth and innovation in the industry.